Levodopa-Reduced Mucuna pruriens Seed Extract Shows Neuroprotective Effects against Parkinson’s Disease in Murine Microglia and Human Neuroblastoma Cells, Caenorhabditis elegans, and Drosophila melanogaster by Johnson, Shelby L. et al.
University of Rhode Island
DigitalCommons@URI
Biomedical and Pharmaceutical Sciences Faculty
Publications Biomedical and Pharmaceutical Sciences
2018
Levodopa-Reduced Mucuna pruriens Seed Extract
Shows Neuroprotective Effects against Parkinson’s
Disease in Murine Microglia and Human
Neuroblastoma Cells, Caenorhabditis elegans, and
Drosophila melanogaster
Shelby L. Johnson
University of Rhode Island, shelby_johnson@uri.edu
Hyun Y. Park
See next page for additional authors
Creative Commons License
Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.
Follow this and additional works at: https://digitalcommons.uri.edu/bps_facpubs
This Article is brought to you for free and open access by the Biomedical and Pharmaceutical Sciences at DigitalCommons@URI. It has been accepted
for inclusion in Biomedical and Pharmaceutical Sciences Faculty Publications by an authorized administrator of DigitalCommons@URI. For more
information, please contact digitalcommons@etal.uri.edu.
Citation/Publisher Attribution
Johnson, S.L.; Park, H.Y.; DaSilva, N.A.; Vattem, D.A.; Ma, H.; Seeram, N.P. Levodopa-Reduced Mucuna pruriens Seed Extract Shows
Neuroprotective Effects against Parkinson’s Disease in Murine Microglia and Human Neuroblastoma Cells, Caenorhabditis elegans, and
Drosophila melanogaster. Nutrients 2018, 10, 1139.
Available at: https://doi.org/10.3390/nu10091139
Authors
Shelby L. Johnson, Hyun Y. Park, Nicholas A. DaSilva, Dhiraj A. Vattem, Hang Ma, and Navindra P. Seeram
This article is available at DigitalCommons@URI: https://digitalcommons.uri.edu/bps_facpubs/53
nutrients
Article
Levodopa-Reduced Mucuna pruriens Seed Extract
Shows Neuroprotective Effects against Parkinson’s
Disease in Murine Microglia and Human
Neuroblastoma Cells, Caenorhabditis elegans,
and Drosophila melanogaster
Shelby L. Johnson 1,2,3 ID , Hyun Y. Park 4,5, Nicholas A. DaSilva 2,3 ID , Dhiraj A. Vattem 4,5,*,
Hang Ma 1,2,3,* ID and Navindra P. Seeram 2,3,*
1 School of Biotechnology and Health Sciences, Wuyi University; International Healthcare Innovation
Institute (Jiangmen), Jiangmen 529020, China; shelby_johnson@uri.edu
2 Bioactive Botanical Research Laboratory, Department of Biomedical and Pharmaceutical Sciences,
College of Pharmacy, University of Rhode Island, Kingston, RI 02881, USA; ndasilva@my.uri.edu
3 George and Anne Ryan Institute for Neuroscience, University of Rhode Island, Kingston, RI 02881, USA
4 Edison Biotechnology Institute, Ohio University, Athens, OH 45701, USA; parkh4@ohio.edu
5 School of Applied Health Sciences and Wellness, Ohio University, Athens, OH 45701, USA
* Correspondence: vattem@ohio.edu (D.A.V.); hang_ma@uri.edu (H.M.); nseeram@uri.edu (N.P.S.);
Tel.: +1-740-593-0133 (D.A.V.); +1-401-874-7654 (H.M.); +1-401-874-9367 (N.P.S.)
Received: 16 July 2018; Accepted: 17 August 2018; Published: 22 August 2018


Abstract: Mucuna pruriens (Mucuna) has been prescribed in Ayurveda for various brain
ailments including ‘kampavata’ (tremors) or Parkinson’s disease (PD). While Mucuna is a
well-known natural source of levodopa (L-dopa), published studies suggest that other bioactive
compounds may also be responsible for its anti-PD effects. To investigate this hypothesis,
an L-dopa reduced (<0.1%) M. pruriens seeds extract (MPE) was prepared and evaluated for its
anti-PD effects in cellular (murine BV-2 microglia and human SH-SY5Y neuroblastoma cells),
Caenorhabditis elegans, and Drosophila melanogaster models. In BV-2 cells, MPE (12.5–50 µg/mL)
reduced hydrogen peroxide-induced cytotoxicity (15.7−18.6%), decreased reactive oxygen species
production (29.1−61.6%), and lowered lipopolysaccharide (LPS)-induced nitric oxide species release
by 8.9–60%. MPE (12.5−50 µg/mL) mitigated SH-SY5Y cell apoptosis by 6.9−40.0% in a non-contact
co-culture assay with cell-free supernatants from LPS-treated BV-2 cells. MPE (12.5−50 µg/mL)
reduced 6-hydroxydopamine (6-OHDA)-induced cell death of SH-SY5Y cells by 11.85–38.5%.
Furthermore, MPE (12.5−50 µg/mL) increased median (25%) and maximum survival (47.8%) of
C. elegans exposed to the dopaminergic neurotoxin, methyl-4-phenylpyridinium. MPE (40 µg/mL)
ameliorated dopaminergic neurotoxin (6-OHDA and rotenone) induced precipitation of innate
negative geotaxis behavior of D. melanogaster by 35.3 and 32.8%, respectively. Therefore, MPE contains
bioactive compounds, beyond L-dopa, which may impart neuroprotective effects against PD.
Keywords: Mucuna pruriens; levodopa; Parkinson’s disease; neuroprotection; Caenorhabditis elegans;
Drosophila melanogaster
1. Introduction
Parkinson’s disease (PD) is a progressive neurodegenerative disease that leads to impaired
motor function and is characterized by a loss of dopaminergic neurons in the substantia nigra and
is second only to Alzheimer’s disease in its prevalence [1]. The etiology and pathophysiology
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of PD are not very well understood and have consequently stifled the development of effective
therapeutic interventions for PD. Accumulating evidence suggests that elevated oxidative stress and
neuroinflammation associated with microgliosis and intracellular aggregation of α-synuclein molecules
may be responsible for dopaminergic neuronal atrophy and ultimately the clinical manifestation of
PD [2–4].
Mucuna pruriens, commonly known as Mucuna or velvet bean, is native to eastern India and
western regions of China. Mucuna seeds, a rich source of naturally occurring levodopa (L-dopa;
4–7% in Mucuna seeds) [5], have been used traditionally as an effective remedy for several brain
related maladies, including reducing tremors (as seen in PD), as documented in the ancient treatise
of Ayurveda, the Indian traditional system of medicine [6]. The lack of effective pharmaceutical
treatments has stimulated research interest in Mucuna as a PD therapeutic agent in several animal
studies and a limited number of human clinical trials [7–9]. For example, Mucuna, at a dosage of
17.5 mg/kg, improved motor function and reduced dyskinesia in patients with advanced PD with
fewer adverse effects as compared with the conventional treatment of L-dopa paired with a dopamine
decarboxylase inhibitor, namely Carbidopa [9]. Mucuna has also been reported to show protective
effects against PD in rodent models by increasing the activity of brain mitochondrial complex-I [10]
and reducing motor dysfunction [11,12]. While several studies have attributed the anti-PD activities to
naturally occurring high levels of L-dopa in Mucuna, emerging evidence suggests that other bioactive
compounds besides L-dopa may also have neuroprotective effects. For example, a Mucuna methanolic
extract (0.1% dosage) containing low levels of L-dopa (0.01%) showed anti-PD effects including
improvements of motor function and olfactory response in a Drosophila melanogaster genetic model of
PD [13]. The anti-PD effects of the Mucuna methanolic extract were superior to that of the treatment of
L-dopa (0.01%) alone in the aforementioned D. melanogaster model, suggesting that the overall anti-PD
effects of Mucuna were a result of other compounds beyond L-dopa alone [13].
Our group has previously reported on the development of a neuroprotective potential algorithm
for several Ayurvedic botanical extracts, among which M. pruriens ranked in the top four [14]. Given
our group’s research interest in this medicinal plant, and to explore the role of its ‘non-L-dopa’
bioactives against PD, we prepared a M. pruriens seed extract (MPE) containing low amounts of
L-dopa (<0.1%) with the following objectives: (1) to evaluate the antioxidant and anti-inflammatory
effects of MPE in murine microglia (BV-2) and human neuroblastoma (SH-SY5Y) cells; (2) to assess the
neuroprotective effects of MPE against neurotoxin-induced cytotoxicity in cellular PD models; and (3)
to evaluate the neuroprotective effects of MPE using Caenorhabditis elegans and D. melanogaster models
of chemically induced PD.
2. Materials and Methods
2.1. Chemicals
Dimethylsulfoxide (DMSO), levodopa (L-dopa), Resveratrol (Resv), lipopolysaccharide (LPS),
2′,7′-dichlorofluorescin diacetate (DCF-DA), hydrogen peroxide (H2O2), 6-hydroxydopamine
(6-OHDA), 1-methyl-4-phenylpyridinium (MPP+), and rotenone were purchased from
Sigma-Aldrich Chemical Co. (St. Louis, MO, USA). Dulbecco’s modified Eagle’s medium
(DMEM)/F-12, phenol red-free DMEM medium and trypsin-versene were purchased from Life
Technologies (Grand Island, NY, USA).
2.2. Preparation of Mucuna pruriens Seeds Extract (MPE)
Mucuna pruriens seeds (3–7% L-dopa) were botanically authenticated and generously provided
by Verdure Sciences (Noblesville, IN, USA). Mucuna pruriens seeds were authenticated by Dr. V.
Singh (Pharmanza, Gujarat, India) with voucher specimen (No. PHPL/HB/013) deposited in the
Heber-Youngken Garden and Greenhouse at the College of Pharmacy, the University of Rhode Island,
RI, USA. Briefly, the ground M. pruriens seeds (150 g) were extracted with sonication in methanol
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(1000 mL) in an ultrasonic bath (Bransonic 8510; Branson Ultrasonics Corp., Danbury, CT, USA) for
0.5 h and macerated in methanol at room temperature for 24 h to afford a crude methanol extract
(6.5 g), which was dried in vacuo (in a water bath at 35 ◦C); reconstituted in water; and then partitioned
sequentially in n-hexanes, ethyl acetate, and butanol with details as follows. The dried crude extract
(6.5 g) was reconstituted in distilled water (250 mL) and sequentially partitioned with n-hexanes, ethyl
acetate, and butanol (250 mL × 3 for each solvent). Each of these fractions, namely, hexanes (0.2 g),
ethyl acetate (0.3 g), butanol (2.9 g), and the remaining water portion (3.0 g), were dried in vacuo (in a
water bath at 35 ◦C) to afford respective extracts. The levels of L-dopa were quantified in each dried
extract (described below) and the extract with the lowest level of L-dopa, namely, MPE (the M. pruriens
ethyl acetate extract; see Table 1), was selected for further biological evaluation.
2.3. Quantification of L-Dopa by Liquid Chromatography Electrospray Ionization Tandem Mass
Spectrometry (LC-ESI-MS/MS)
L-dopa was quantified by liquid chromatography electrospray ionization tandem mass
spectrometry (LC-ESI–MS/MS) using methods and parameters published by our group and others
with some modifications [15–19]. L-dopa quantifications were performed on a prominence ultra-fast
liquid chromatography (UFLC) system (Shimadzu, Marlborough, MA, USA) coupled with a QTRAP
4500 system (Applied Biosystems/MDS Sciex, Framingham, MA, USA) with data acquired using
Analyst 1.6.3 software and processed using MultiQuant 3.0.1 software (Sciex, Framingham, MA, USA).
The UFLC system consisted of three LC-20AD pumps, a DGU-20A degassing unit, SIL-20AC auto
sampler, CTO-20AC column oven, and CBM-20A communication bus module. Chromatographic
separation was performed using a 100 mm × 4.6 mm i.d., 5 µm, XBridge C18 column (Waters, Milford,
MA, USA). The mobile phase consisted of A (water containing 0.1% (v/v) formic acid) and B (methanol
containing 0.1% (v/v) formic acid) with a gradient elution of 1% B from 0 to 10 min, and 1−4% B
from 10 to 20 min. The flow rate was 0.5 mL/min and the injection volume was 10 µL. The column
temperature was maintained at 40 ◦C. The MS operated in electrospray ionization (ESI) in positive
mode with multiple reaction monitoring (MRM). Nitrogen was used as the source gas in all cases.
Parameters were optimized as follows: IonSpray voltage, 4500 V; nebulizer gas, 40 psi; auxiliary heater
gas, 45 psi; curtain gas, 20 psi; turbo gas temperature, 300 ◦C. Using an authentic L-dopa standard
(purchased from Sigma-Aldrich Chemical Co.; St. Louis, MO, USA), L-dopa was analyzed by the
multiple reaction monitor (MRM) mode using ion transition at m/z values of 198/152. All of the
analyses of the standard and extracts were performed in triplicates (see LC-ESI-MS/MS spectra in the
Supplementary Materials; Figure S1). The calibration curve (y = 5006.29x − 13189.13; R = 0.99825) was
acquired by plotting the peak area against the nominal concentrations of L-dopa. The linearity was
in the range of 10–1000 ng/mL. The presence of L-dopa in Mucuna extracts was identified as a peak
with a retention time of 3.95 min under the ion transition 198/152. The percentage of L-dopa in the
different Mucuna extracts was calculated as follows: (ng/mL of L-dopa in extract)/(µg/mL of extract
injected) × 100%.
2.4. Cell Culture
Murine microglia (BV-2) cells were kindly provided by Dr. Grace Y. Sun (University of Missouri
at Columbia, MO, USA) and human neuroblastoma (SH-SY5Y) cells were purchased from American
Type Culture Collection (ATCC, Manassas, VA, USA). Cells were maintained at 37 ◦C in 5% CO2 with
high glucose (4.5 g/L) DMEM/F-12 accompanied with 10% heat inactivated fetal bovine serum, and
1% P/S (100 U/mL penicillin, 100 mg/mL streptomycin) (Life Technologies, Gaithersburg, MD, USA).
MPE was dissolved in distilled water to obtain a 10 mg/mL stock solution and further diluted in
serum free media for treatments. Resv (used as a positive control for the cellular based assays) was
dissolved in DMSO (10 mM) and diluted in media to the desired concentration. Control cells were
treated with 0.1% DMSO in serum free media.
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2.5. Cell Viability
BV-2 and SH-SY5Y cells were seeded in white walled 96-well plates at 1 × 105 cells/mL in serum
free media. MPE (12.5, 25, and 50 µg/mL) were evaluated for cytotoxicity effects in BV-2 and SH-SY5Y
cells. After 24 h, cell viability was determined using Cell Titer Glo 2.0 (CTG; Promega, Madison, WI,
USA) according to methods previously reported by our group [14,20]. MPE was then evaluated for
its cellular protective effects against several oxidative insults as follows. Cells were pretreated with
MPE (12.5, 25, and 50 µg/mL), Resv (20 µM), or solvent control (0.1% DMSO) for either 1 h (in BV-2
cells) or 2 h (in SH-SY5Y cells). Cellular oxidative stress was induced in BV-2 and SH-SY5Y with H2O2
(100 µM), SH-SY5Y with 6-OHDA (25 µM), and MPP+ (2 mM). Cellular viability of BV-2 and SH-SY5Y
cells after treatment were determined at 6 and 24 h, respectively, by the aforementioned CTG assay.
2.6. Determination of Hydrogen Peroxide (H2O2)-Induced Reactive Oxygen Species (ROS) in Murine
Microglia BV-2 Cells
The production of H2O2-induced reactive oxygen species (ROS) in BV-2 cells was determined by a
fluorescent probe (DCF-DA) using previously reported method with modifications [21]. BV-2 microglial
cells were seeded in a black 96-well plate at 1 × 105 cells/mL in serum free media. Cells were allowed
to attach for 24 h and pretreated with MPE (12.5, 25, and 50 µg/mL), Resv (20 µM), or solvent control
(0.1% DMSO) for 1 h. Next, DCF-DA (20 µM) was added to each well and incubated for 25 min.
Cells were then washed with PBS and incubated with H2O2 (100 µM) for 6 h. The fluorescence signal
of each cell was measured at excitation and emission wavelengths of 495 nm and 529 nm, respectively,
using a SpectraMax M2 plate reader (Molecular Devices, Sunnyvale, CA, USA).
2.7. Measurement of Lipopolysaccharide (LPS)-Induced Nitric Oxide Species (NOS) in Murine Microglia
BV-2 Cells
The production of total nitric oxide species (NOS) was determined using the Griess reagent
as previously reported by our group [14,20]. BV-2 cells were seeded in clear 24-well plates at
1 × 105 cells/mL in serum free media. Cells were treated with MPE (12.5, 25, and 50 µg/mL),
Resv (20 µM), or solvent control (0.1% DMSO) for 1 h. The cells were exposed to inflammatory stress
induced by treating with LPS (1 µg/mL) for 24 h. Next, culture media from each well were transferred
to a 96-well plate and measured for total NOS using the Griess reagent kit (Promega, Fitchburg, WI,
USA). Absorbance values were recorded using the SpectraMax M2 plate reader (Molecular Devices,
Sunnyvale, CA, USA) at 535 nm.
2.8. Non-Contact Co-Culture Assay with BV-2 and SH-SY5Y Cells
The non-contact co-culture assay was performed according to protocols previously reported by
our group [22]. Briefly, SH-SY5Y cells were seeded in white wall and clear bottom 96-well plates
and allowed to adhere for 24 h. BV-2 cells were plated in 24 well plates and treated with MPE (12.5,
25, and 50 µg/mL), Resv (20 µM), or solvent control (0.1% DMSO), followed by LPS (1 µg/mL)
treatment for 24 h. Media from each treatment was collected and centrifuged at 15,000 rpm for 10 min.
After centrifugation, BV-2 cell supernatant was used to treat SH-SY5Y cells for 24 h. Cellular viability
of SH-SY5Y cells was determined using the CTG assay.
2.9. 1-Methyl-4-Phenylpyridinium (MPP+) Induced Dopaminergic Neurotoxicity in C. elegans
Wild type C. elegans (N2) were maintained on nematode growth media culture plates at 20 ◦C
and age synchronized as previously reported by our group [22]. Then, 40 µL of age synchronized L1
worms washed in S-complete were transferred to a 96-well microplate (approximately 20 worms/well)
with Escherichia coli OP50 (5 mg/mL), MPP+ (750 µM), and MPE (20 or 40 µg/mL) to a final volume
of 50 µL. S-complete media was used for control groups. Live worms were counted every 12 h post
treatment until no live worms remained.
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2.10. D. melanogaster Strains and Maintenance
Wild type STR-5 flies were obtained from the Bloomington Stock Center (Department of Biology,
Indiana University, Bloomington, IN, USA). Strains were reared on Formula 4-24® Instant Drosophila
Medium (Carolina Biological Supply, Burlington, NC, USA) and reared on Bloomington Formulation
(Genesee Scientific, San Diego, CA, USA) at 25 ◦C with 75% humidity and a 12-hour light/dark
cycle [23]. Approximately 40–50 mating pairs were transferred into flasks and allowed to lay eggs.
After nine days, newly eclosed male flies were collected over a period of three days and used in
further experiments.
2.11. Negative Geotaxis (Climbing) Assay in D. melanogaster
Newly eclosed wild type (STR-5) male flies were randomly separated into 10 groups of 50 flies
each and transferred to control flasks (media only) or in treatment flasks (media + 40 µg/mL MPE).
To induce neurotoxicity, every four days, flies were starved in empty vials for 24 h and transferred
into vials containing a filter paper saturated with 1 mL of 10% sucrose (blank), 6-OHDA (1 mM),
or rotenone (500 µM). After 24 h, the flies were transferred into vials with a fresh supply of their
respective diets and used for climbing assay on day 10 post-eclosion. Flies from control and treatment
groups were then tapped into the bottom of graduated cylinder (diameter: 2.7 cm, height: 25 cm)
superimposed with a ruler and allowed to climb for 10 s. Flies were photographed (Canon, Inc., Tokyo,
Japan, JP, EOS 50D; 15.1 MP Digital SLR) at t0 and t10 seconds to calculate the climbing distance [24].
2.12. Statistical Analyses
All data are presented as mean± standard errors of three separate biological samples. Analyses of
cellular data were conducted by analysis of variance (ANOVA) followed by Dunnett’s test for multiple
comparisons of group means. The Kaplan–Meier method was used to compare the survival curves of
C. elegans and the survival differences were tested for statistical significance using the log rank test
(Mantel Cox). For the D. melanogaster climbing assay, Welch’s t-test was used to compare the different
treatment groups and generate p values (alpha = 0.05). Significance compared with control group is
presented as p≤ 0.05 (#), p≤ 0.001 (###), and p≤ 0.0001 (####). Significance for all tests compared with
toxic treatment was defined as follows: p ≤ 0.05 (*), p ≤ 0.01 (**), p ≤ 0.001 (***), and p ≤ 0.0001 (****).
GraphPad Prism software 6.0 (GraphPad Software, Inc., San Diego, CA, USA) was used to calculate
statistics for both the in vitro and in vivo analyses.
3. Results and Discussion
3.1. Preparation of Levodopa (L-Dopa)-Reduced Mucuna pruriens Extract (MPE)
Mucuna pruriens is a medicinal plant that is well known to naturally contain L-dopa (4–7%) [5],
which might be attributed to its neuroprotective effects against PD [6]. However, the presence of other
phytochemicals in M. pruriens, including polyphenols (tannins, flavonoids, gallic acid, phenolic acids),
saponins, terpenoids, alkaloids, and fatty acids, have been reported with various pharmacological
activities (see Supplementary Materials; Figure S2 and Table S1) [6,25–29]. Recent studies also suggest
that phytochemicals apart from L-dopa may also contribute to the overall neuroprotective activities of
M. pruriens [13,30]. Therefore, in this study, we prepared a M. pruriens seed extract (MPE) containing
reduced L-dopa levels (<0.1%), which was subsequently evaluated for its neuroprotective effects
using a panel of in vitro and in vivo assays. The seeds of M. pruriens were extracted/solvent-solvent
partitioned in varying solvents to yield extracts, which were evaluated for L-dopa content by liquid
chromatography electrospray ionization tandem mass spectrometry (LC-ESI–MS/MS). As shown
in Table 1, the L-dopa levels in the initial methanol M. pruriens seeds extract was 28.0%, which was
significantly reduced to 0.03% in the ethyl acetate M. pruriens extract (MPE). As even this low level
(0.03%) of L-dopa could impart biological effects, we evaluated a pure L-dopa solution (<0.1%) in
several of the in vitro assays. Our preliminary data showed that the MPE, but not this pure L-dopa was
Nutrients 2018, 10, 1139 6 of 14
active in these assays (data shown in Supplementary Materials Figures S5 and S6). Therefore, this MPE
extract was selected for further evaluation of its neuroprotective effects in a panel of cell-based and
in vivo bioassays as described below.
Table 1. Levodopa (L-dopa) content for each Mucuna pruriens seed extracts as determined by liquid
chromatography electrospray ionization tandem mass spectrometry (LC-ESI-MS/MS).
Extract Yield (%; w/w) L-Dopa Content (%; w/w)
methanol 100 28.0
hexanes 3.1 0.54
ethyl acetate 4.7 0.03
butanol 45.3 10.05
water 46.9 21.39
3.2. MPE Reduces Hydrogen Peroxide (H2O2)-Induced Toxicity and Reactive Oxygen Species (ROS)
Production in Microglia BV-2 Cells
Microglia are the native immune cells of the central nervous system (CNS) that undergo activation
and proliferation to carry out phagocytosis, release inflammatory cytokines, and produce ROS and
reactive nitrogen species (RNS) in response to injury and/or infection. Unresolved inflammation and
excessive oxidant production by microglia are lethal to both neuronal and non-neuronal cells in the
CNS and have been associated with PD. All of the Mucuna extracts including the crude methanol,
hexanes, ethyl acetate (MPE), butanol, and water extracts (at 25 µg/mL) were evaluated for their
protective effects against H2O2-induced toxicity in BV-2 cells. Our data showed that among the extracts,
only the MPE significantly increased the viability of BV-2 cells exposed to H2O2 (see Supplementary
Materials Figure S3A). Therefore, we evaluated the effects of MPE on oxidative stress induced by H2O2
in microglia BV-2 cells. MPE (12.5, 25, and 50 µg/mL) was non-toxic to BV-2 cells with cell viability
greater than 90.3% at 24 h (Figure 1A). As shown in Figure 1B, the cell viability of H2O2-treated BV-2
cells decreased by 39.2%, as compared with the control group. Although MPE, at concentrations of 12.5,
25, and 50 µg/mL, showed a trend to ameliorate the H2O2-induced cytotoxicity in BV-2 cells, only MPE
at a concentration of 25 µg/mL significantly increased the cell viability of H2O2-treated BV-2 cells,
by 18.6%. The protective effects of MPE against the production of ROS by H2O2 in BV-2 cells were then
evaluated. As shown in Figure 1C, the production of ROS in H2O2-treated BV-2 cells was elevated by
3.29-fold as compared with the control cells. MPE (12.5, 25, and 50 µg/mL) reduced the H2O2-induced
production of ROS by 35.5, 29.1, and 61.6%, respectively, compared with the H2O2-treated BV-2 cells.
Resveratrol (Resv; 20 µM), used as the positive control, reduced the H2O2-induced production of ROS
by 44.52%. These results are in agreement with our previous observation, wherein an M. pruriens water
extract increased viabilities of murine BV-2 microglia and differentiated human SH-SY5Y neuronal
cells that exposed to H2O2 [14]. Moreover, studies from other research groups also reported that
Mucuna seeds powder (300 mg/kg/BW in diet) reduced oxidative stress in rodent sperm cells [31].
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contr l group (contr l 8.987 µM vs. LPS 40.06 µM). MPE (12.5, 25, and 50 µg/mL) reduced th NOS
production in LPS-stimulated BV-2 cells by 8.9, 37.8, and 60.1%, respectively, as compared with the
cells treated with LPS alone. Resv (positive control; 20 µM), also reduced the NOS production by 43.2%
in the LPS-treated BV-2 cells and was similar to our previous observation [22]. In the non-contact
c -culture model (Figure 2B), conditione media collected from BV-2 cells treated with LPS alone
reduced the cell viability of SH-SY5Y cells by 43.1%. The conditioned me ia from treatment of LPS
and MPE (12.5, 25 and 50 µg/mL) significantly increased the cellular viability of SH-SY5Y cells by
19.4, 23.2%, and 40.1%, respectively, as compared with the cells treated with media from LPS-treated
BV-2 cells. The positive control, Resv (20 µM), also increased the cell viability of SH-SY5Y cells by
29.3%. Our results support other studies on Mucuna reporti g a reduction in nitrite levels induced by
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1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the nigrostriatal region of Parkinsonian mice
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. . e ces i ati e tress I ce toto icit i - ells
e er l neurot xins, including 6-OHDA and MPP, induce oxidative cytotoxicity in d paminergic
neurons by multiple mechanisms and thus are used to model PD [2,34,35]. The protective effects of
MPE were evaluated in SH-SY5Y ne roblastoma cells against oxidative stress induced neurotoxicity.
MPE (12.5, 25, and 50 µg/mL) did not induce cytotoxicity of SH-SY5Y cells after 24 h incubation
(viability >90%) in the CTG assay (Figure 3A). Toxicity was induced in SH-SY5Y neuroblastoma by
treatment with 6-OHDA, H2O2, and MPP+ (25 µM, 100 µM, and 2 mM, respectively). Treatment of
6-OHDA signific ntly reduced the viability of SH-SY5Y cells by 71.9% as compared with the control
group, while MPE (12.5, 25, and 50 µg/mL) reduced 6-OHDA-induced cell death of SH-SY5Y cells
by increasing cell viabilit compared with the 6-OHDA treated group by 11.9%, 38.5%, and 23.9%,
respectively (Figure 3B). Treatment of H2O2 reduced SH-SY5Y cells viability by 65.1% as compared
with control, while MPE (at higher concentrations of 25 and 50 µg/mL) showed moderate protective
effects by increasing SH-SY5Y cell viability compared with cell viability of the H2O2 treated group
by 19.5% and 16.3%, respectively (Figure 3C). MPP+ treatment significantly reduced the viability of
SH-SY5Y cells by 46.7% as compared with control (Figure 3D); owever, MPE showed no protective
effects. Our findings obtained from these cellular PD models are in agreement with previously
reported neuroprotective effects of Mucuna in neurotoxins-induced PD animal mo els. For example,
Mucuna treatment reduced 6-OHDA-i duced L-dopa depletion in nigrostriatal tract of rats with PD
symptoms [10,33].
Nutrients 2018, 10, 1139 9 of 14
Nutrients 2018, 10, x FOR PEER REVIEW  9 of 14 
 
 
Figure 3. Effects of MPE (12.5, 25, and 50 μg/mL) on cellular viability of SH-SY5Y human 
neuroblastoma cells against toxic models of Parkinson’s disease. Effects of MPE (12.5, 25, and 50 
μg/mL) alone on SH-SY5Y cell viability (A), of MPE after 6-OHDA-induced toxicity (B), of MPE 
against H2O2-induced toxicity (C), and of MPE against MPP+ induced toxicity (D). Data shown as 
mean ± standard error (n = 3), significance was reported by ANOVA and subsequent Dunnett multiple 
as compared with control p ≤ 0.001 (###), and p ≤ 0.0001 (####); as compared with toxic agent, p ≤ 0.05 
(*), and p ≤ 0.01 (**). 
3.5. MPE Reduces Lethality of MPP+ Induced Dopaminergic Neurotoxicity in C. elegans 
The neurotoxin, MPTP, is metabolized to MPP+ by monoamine oxidase-B and is subsequently 
taken up by dopaminergic neurons, where it inhibits mitochondrial complex I, resulting in ATP 
depletion to induce neuronal death [35]. Therefore, we evaluated the effects of MPE against MPP+ 
dopaminergic neurotoxicity in wild type C. elegans. The effects of MPE in MPP+ induced neurotoxic 
paralysis and lethality in C. elegans were evaluated at concentrations of 20 and 40 μg/mL (IC10 = 42.1 
μg/mL). The median and maximum survival of worms after exposure to 750 μM MPP+ was 72 h 
(Table 2). 
Table 2. Survival (median and maximum) of C. elegans (N2), as compared with 1-methyl-4-
phenylpyridinium (MPP+) treatment (750 μM). MPE treatment at both 20 and 40 μg/mL significantly 
increased survival, as determined by log rank test (Mantel Cox), n > 100, p ≤ 0.05 (*), p ≤ 0.001 (***). 
Survival (h) MPP+ MPP
+ + MPE 
(20 μg/mL) 
MPP+ + MPE 
(40 μg/mL) 
Median 72 96 * 138 *** 
Maximum 72 132 * 162 *** 
Treatment of MPP+ significantly reduced the median and maximum survival by 3.2-fold (72 h) 
and 3.5-fold (72 h), respectively, compared with worms in the control group (Figure 4A). MPE at 20 
μg/mL significantly increased (p < 0.001) the median and maximum survival by 1.3-fold (96 h) and 
1.9-fold (138 h), respectively, compared with worms treated with MPP+ alone (Figure 4B). MPE at 40 
μg/mL significantly increased the mean and maximum survival in C. elegans by 1.8-fold (132 h) and 
Figure 3. Effects of PE (12.5, 25, and 50 µg/mL) on cellular viability of S -S 5 hu an
e roblasto a cells against toxic models of Parkinso ’s disease. Effects of MPE (12.5, 25, and 50 µg/mL)
alone on SH-SY5Y cell viability (A), of MPE after 6-OHDA-induced toxicity (B), of MPE against
H2O2-induced toxicity (C), and of MPE against MPP+ induced toxicity (D). Data sho s
standard e ror (n = 3), significance was reported by ANOVA and subseque t tt lti l
it control p ≤ . ( ), 0.000 ( #); s it t i e t, p .
, 0.01 ( *).
3.5. PE Reduces Lethality of PP+ Induced Dopaminergic Neurotoxicity in C. elegans
The neurotoxin, PTP, is etabolized to PP+ by onoa ine oxidase-B and is subsequently
taken up by dopa inergic neurons, here it inhibits itochondrial co plex I, resulting in ATP
depletion to induce neuronal death [35]. Therefore, we evaluated the effects of MPE against
MPP+ dopaminergic neurotoxicity in wild type C. elegans. The effects of MPE in MPP+ induced
neurotoxic paralysis and lethality in C. elegans were evaluated at concentrations of 20 and 40 µg/mL
(IC10 = 42.1 µg/mL). The median and maximum survival of worms after exposure to 750 µM MPP+
was 72 h (Table 2).
a le 2. Survival (median and maximum) of C. elegans ( 2), as co pared ith 1- et yl-4-
l ri i i ( ) tr t t ( µ ). tr t t t t µ si ifi tl
i i l, t i l t t ( t l ), , 0.05 (*), p ≤ . 01 (***).





Median 72 96 * 138 ***
Maximum 72 132 * 162 ***
Treatment of MPP+ significantly reduced the median and maximum survival by 3.2-fold (72 h)
and 3.5-fold (72 h), respectively, compared with worms in the control group (Figure 4A). MPE at
20 µg/mL significantly increased (p < 0.001) the median and maximum survival by 1.3-fold (96 h)
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and 1.9-fold (138 h), respectively, compared with worms treated with MPP+ alone (Figure 4B). MPE at
40 µg/mL significantly increased the mean and maximum survival in C. elegans by 1.8-fold (132 h) and
2.25-fold (162 h) respectively, compared with worms treated with MPP+ alone (Figure 4C and Table 2).
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effects of therapeutics [36]. As MPE wa significantly more neuroprotective at 40 µg/mL in reducing
MPP+ induced dopaminergic neurotoxicity in C. elegans (Figure 4), we used this dosage to determine
its effect n climb g behavior ( egative eotaxis) in D. melanogaster neurotoxin i duced PD model.
The two neurotoxins (6-OHDA and rotenone) used in ur study in uce a PD-like phenotype in
D. melanogaster characterized by several behavioral changes including a muted innate negative geotaxis
respons due to locomotor defects. The af rementioned toxins gen rally injure dopamine neurons
and cause behavioral defects including climbing, whi h ca be measured by neg tive geot xis assay.
Similar to MPP+, rotenone is ano her mitochondrial complex I inhibit r that causes ATP impairment
and ROS production, a d i uces neuronal death [35]. In our study, D. melanogaster we e exposed
to 6-OHDA and roten ne to induce PD like phenotype. After 10 days, flies ex osed to neurotoxins
showed a highly muted climbing ability compared with control group. This loss of negative geotaxis
ability was significantly ame orated when flies were pre-treated with MPE.
The istance in 6-OHDA treated flies and rote one tr ated flies was 18.6%
(8.7 cm; p ≤ 0.05) and 37.8% (6.2 cm, p ≤ 0.001) lower tha in control flies (10.95 cm), respect vely
(Figu 5). Treatment of MPE alone significantly incr ased the climbing distance in flies by 42.5%
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(15.9 cm) compared with the control group (Figure 5). Pre-treatment with MPE abrogated the effect of
neurotoxins on climbing behavior. In the MPE + 6-OHDA treated flies, the median climbing distance
was 54.5% (13.95 cm) higher as compared with flies that were treated with 6-OHDA alone (Figure 5).
In the MPE + rotenone treated flies, this was 48.7% (9.9 cm) higher than in flies that were exposed to
rotenone only without any MPE pre-treatment (Figure 5). Our results on the neuroprotective effects of
MPE on neurotoxin induced PD models using C. elegans and D. melanogaster support previous studies
with Mucuna in rodent models of PD using MPTP [33] and 6-OHDA [25] and provide further evidence
on the neuroprotective effects of non-L-dopa bioactives in MPE.
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